Future investigations in patient-derived primary tumor cultures, spheroids, and organoids [60,61,62] should also focus on somatic mutations or signaling cascade alterations to characterize predictive biomarkers in neuroendocrine tumors for the therapeutic response to dual MEK inhibition and CDK4/6 inhibition [19,69]. The gene discussed is CDK4; the disease is neuroendocrine neoplasm.